Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the cancer vaccine OSE2101 compared to the chemotherapy drug docetaxel in patients with metastatic non-small cell lung cancer NSCLC who have developed resistance to immune checkpoint inhibitors. This phase 3, randomized, open-label study focuses on HLA-A2 positive patients with either squamous or non-squamous NSCLC who are not candidates for surgery or radiation and lack certain genetic alterations that make them eligible for targeted therapies. Participants will be randomly assigned in a 21 ratio to receive either OSE2101 or docetaxel. OSE2101 is given as a subcutaneous injection every three weeks for six cycles, then every eight weeks for the first year, and finally every twelve weeks until the end of the second year. Docetaxel is administered as an intravenous infusion every three weeks. The study also uses companion diagnostic devices to confirm HLA-A2 status. Throughout the study, participants will have regular visits for treatment and monitoring. Researchers will measure overall survival from randomization until death, with an average follow-up of three years. The trial aims to assess the safety and effectiveness of OSE2101 compared to docetaxel in this patient group, with ongoing monitoring until study completion in late 2028.